Intelligence Feed event · Equity · 2026-10-21

    HUTCHMED closed KRAS-EGFR therapy license to GSK outside China

    Question

    HUTCHMED closed KRAS-EGFR therapy license to GSK outside China

    Direct answer

    The license shifts development economics and upfront cash into GSK and HCM while expanding the addressable oncology asset for GSK outside Greater China and Taiwan.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-21
    Published
    2026-10-21
    Revision
    1 · 2026-10-21

    Cite as: Market Ontology, “HUTCHMED closed KRAS-EGFR therapy license to GSK outside China”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/hutchmed-closed-kras-egfr-therapy-license-to-gsk-outside-china-8ae06d

    EQUITY
    HUTCHMED closed KRAS-EGFR therapy license to GSK outside China
    The license shifts development economics and upfront cash into GSK and HCM while expanding the addressable oncology asset for GSK outside Greater China and Taiwan.
    GSKHCM
    Impact
    59
    YESTERDAY
    SIG
    82%
    GSKHCM
    HUTCHMED closed KRAS-EGFR therapy license to GSK outside China
    The license shifts development economics and upfront cash into GSK and HCM while expanding the addressable oncology asset for GSK outside Greater China and Taiwan.
    → The license shifts development economics and upfront cash into GSK and HCM while expanding the addressable oncology asset for GSK outside Greater China and Taiwan.
    Impact
    The license shifts development economics and upfront cash into GSK and HCM while expanding the addressable oncology asset for GSK outside Greater China and Taiwan.
    Affected
    GSKHCM
    Transmission
    The license shifts development economics and upfront cash into GSK and HCM while expanding the addressable oncology asset for GSK outside Greater China and Taiwan.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GSKpipeline expansion and oncology royalty optionality via exclusive license rights outside Greater China and TaiwanUp1-4wGSK subsidiary received worldwide rights excluding Greater China and Taiwan to develop and commercialize HMPL-A830.
    HCMupfront cash inflow from the $110 million license paymentUp1-4wHUTCHMED will receive $110 million upfront.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month